What Is Nicotinamide Riboside Studied For? Research Areas, Per the Literature

Nicotinamide Riboside is not approved by the FDA as a medicine for any condition. This page is not guidance. This page is for educational purposes only and is not medical advice; consult a licensed physician about any health decision. The sections below describe what researchers have investigated, organised by research area, with the study type and model or population named alongside each citation.

What Nicotinamide Riboside Is, Biologically

Nicotinamide riboside (NR) is a pyridine nucleoside form of vitamin B3 that cells can convert into nicotinamide adenine dinucleotide (NAD+). A review of NAD+ intermediates described NR and nicotinamide mononucleotide as the two precursors that attracted the most translational interest, and outlined the salvage and biosynthetic routes through which they feed NAD+ pools (PMID 29249689). A broader review of NAD+ metabolism regulation summarised why NAD+ is central to redox reactions and to enzymes that consume it, including sirtuins and PARPs, and discussed the practical challenges of targeting this pathway therapeutically (PMID 39026037).

The rationale for studying NR at all rests on the observation that NAD+ availability changes with age and disease. A review of NAD+ and sirtuins in aging and disease set out the proposed link between declining NAD+ and sirtuin activity, mitochondrial function and age-associated metabolic decline (PMID 24786309). A later overview of NAD+ boosting strategies compared the different precursors and routes that have been examined experimentally (PMID 39693020).

Research Area 1: Oral Bioavailability and NAD+ Elevation

The most reproducible research finding concerns whether oral NR actually reaches the bloodstream and raises NAD+. A study combining mouse experiments with human pharmacokinetics reported that nicotinamide riboside was uniquely and orally bioavailable, and that it increased NAD+ metabolism in both species (PMID 27721479). That work established the blood NAD+ metabolome as a measurable readout rather than an inferred one.

In humans, a randomised, double-blind, placebo-controlled crossover trial in healthy middle-aged and older adults reported that chronic nicotinamide riboside supplementation was well tolerated and effectively elevated NAD+ (PMID 29599478). It is worth separating two distinct questions here: whether a compound moves a biomarker, and whether moving that biomarker changes clinical outcomes. The first has substantial support; the second is where the literature is thinner.

Research Area 2: Metabolic and Obesity Models

Much of the early interest in NR came from rodent metabolic work. A mouse study reported that the NAD+ precursor nicotinamide riboside enhanced oxidative metabolism and protected against high-fat diet-induced obesity (PMID 22682224). The model was diet-induced obesity in mice, not humans with obesity, and the authors framed the findings around mitochondrial and oxidative metabolism endpoints.

NAD+ biology has also been examined alongside the gut microbiome. A 2025 study in diet-induced obesity models reported that the commensal bacterium Roseburia hominis improved host metabolism, situating NAD+ related metabolic pathways within a broader host-microbe context (PMID 39976263). This is animal and microbiological work, not a human metabolic trial of NR.

The review literature has repeatedly flagged the translation gap. The review of NAD+ intermediates noted the therapeutic potential of NMN and NR while emphasising that preclinical metabolic benefits had not been matched by equivalent human outcome data at the time of writing (PMID 29249689).

Research Area 3: Cardiovascular and Vascular Studies

Cardiac NAD+ biology has been studied in genetically manipulated animals. A 2024 mouse study reported that cardiac NAD+ depletion promoted hypertrophic cardiomyopathy and arrhythmias, and that these changes appeared before measurable impairment of bioenergetics (PMID 39294272). That is a model of NAD+ loss rather than a trial of NR supplementation, and it speaks to why NAD+ is considered a cardiac variable of interest.

Peripheral artery disease

The NICE randomized clinical trial tested nicotinamide riboside in participants with peripheral artery disease, reported in 2024 (PMID 38871717). A randomised design in a defined patient population is the strongest form of evidence available for NR in a vascular condition, and readers evaluating claims about circulation or walking performance should look to this trial and its reported results rather than to rodent data.

Research Area 4: Lung and Airway Inflammation

A randomized, placebo-controlled trial published in 2024 examined the effect of nicotinamide riboside on airway inflammation in chronic obstructive pulmonary disease (PMID 39548320). The population was people with COPD, and the endpoints concerned airway inflammation rather than symptom cure or disease reversal. This trial is one of the few placebo-controlled human studies of NR in a specific inflammatory respiratory condition.

Research Area 5: Aging Biology

NR is frequently discussed in the context of aging, but the human evidence base is biomarker-oriented. The review of NAD+ and sirtuins in aging and disease described the mechanistic case linking NAD+ decline to age-related dysfunction (PMID 24786309). The healthy middle-aged and older adult trial reported tolerability and NAD+ elevation, which are mechanistic and safety endpoints rather than demonstrations of extended healthspan (PMID 29599478). The 2024 review of NAD+ metabolism explicitly discussed the challenges in targeting this pathway, including uncertainty about which tissues respond and how precursor availability translates into functional change (PMID 39026037).

Research Area 6: Cancer Metabolism Context

NAD+ metabolism intersects with tumour biology, which is one reason reviews urge caution rather than enthusiasm. A metabolomic study of eyelid basal cell carcinoma characterised the metabolic signature of these tumours, including nicotinamide-related metabolites (PMID 32649951). That was a tissue-level descriptive study in human samples, not a supplementation trial, and it does not establish either benefit or harm from NR. The broader NAD+ review discussed the two-sided nature of NAD+ targeting, where some strategies aim to raise NAD+ and others to deplete it in proliferating cells (PMID 39026037).

Where the Evidence Is Weak or Absent

Several commonly searched uses are not supported by the verified literature summarised here. There is no trial in this citation set examining nicotinamide riboside for cognitive performance, mood, sleep quality, athletic performance, hair, skin appearance or weight loss in humans. The obesity-related evidence is a mouse study of diet-induced obesity (PMID 22682224) and should not be read as a human weight outcome. Where reviews mention therapeutic potential, they describe it as potential: the NAD+ intermediates review framed NMN and NR as candidates whose clinical value remained to be established (PMID 29249689), and the NAD+ boosting strategies overview catalogued approaches rather than confirming outcomes (PMID 39693020).

Research Areas at a Glance

Tolerability and Adverse Events: What Studies Report

In the randomised crossover trial in healthy middle-aged and older adults, researchers reported that chronic nicotinamide riboside supplementation was well tolerated while elevating NAD+ (PMID 29599478). The combined mouse and human bioavailability study characterised the NAD+ metabolome response to oral nicotinamide riboside and distinguished it from other B3 vitamers (PMID 27721479). Randomised trials in specific patient groups, including the peripheral artery disease trial (PMID 38871717) and the COPD airway inflammation trial (PMID 39548320), carry their own safety reporting, and the 2024 review of NAD+ metabolism noted that targeting this pathway raises unresolved questions that ongoing trials are designed to address (PMID 39026037). Tolerability in a controlled trial population does not generalise automatically to other groups, to longer durations or to people with other conditions.

How to Read This Literature

• Separate biomarker from outcome. NAD+ elevation was reported in human work (PMID 29599478); clinical outcomes were tested separately in disease-specific trials (PMID 38871717).
• Check the species. Metabolic protection against diet-induced obesity was a mouse finding (PMID 22682224).
• Check whether NR was given at all. Several NAD+ papers manipulate NAD+ genetically or describe tissue metabolism without administering nicotinamide riboside (PMID 39294272).
• Reviews summarise, they do not prove. Overviews of NAD+ boosting strategies collate approaches across evidence tiers (PMID 39693020).

Summary

Across the cited literature, nicotinamide riboside has been studied as an orally bioavailable NAD+ precursor (PMID 27721479), as a chronic supplement that elevated NAD+ in healthy middle-aged and older adults (PMID 29599478), in animal models of diet-induced obesity (PMID 22682224), and in randomised trials in peripheral artery disease (PMID 38871717) and COPD airway inflammation (PMID 39548320). Nicotinamide Riboside is not approved by the FDA as a medicine for any condition. This page is not guidance. This page is for educational purposes only and is not medical advice; consult a licensed physician with questions about any supplement or medical condition.

References

• Nicotinamide riboside is uniquely and orally bioavailable in mice and humans (Nature Communications, 2016)
• NAD+ and sirtuins in aging and disease (Trends in Cell Biology, 2014)
• Roseburia hominis improves host metabolism in diet-induced obesity (Gut Microbes, 2025)
• Effect of nicotinamide riboside on airway inflammation in COPD: a randomized, placebo-controlled trial (Nature Aging, 2024)
• Regulation of and challenges in targeting NAD+ metabolism (Nature Reviews Molecular Cell Biology, 2024)
• Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults (Nature Communications, 2018)
• The NAD+ precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity (Cell Metabolism, 2012)
• Nicotinamide riboside for peripheral artery disease: the NICE randomized clinical trial (Nature Communications, 2024)
• Cardiac NAD+ depletion in mice promotes hypertrophic cardiomyopathy and arrhythmias prior to impaired bioenergetics (Nature Cardiovascular Research, 2024)
• NAD+ Boosting Strategies (Sub-cellular Biochemistry, 2024)
• NAD+ Intermediates: The Biology and Therapeutic Potential of NMN and NR (Cell Metabolism, 2018)
• Metabolic signature of eyelid basal cell carcinoma (Experimental Eye Research, 2020)